Lupin Limited, a leading global pharmaceutical company, announced today the appointment of Christoph Funke as their new Chief Technology Officer (CTO), effective immediately.
In this key leadership role, Funke will spearhead Lupin’s global technology strategy, driving digital transformation initiatives and leveraging cutting-edge technologies to enhance operational efficiencies, product development, and overall business growth.
Funke brings over two decades of extensive experience in building and leading high-performing technology teams across the pharmaceutical and healthcare industries. He joins Lupin from Merck KGaA, where he served as the Vice President of Digital Transformation and IT Operations.
“We are thrilled to welcome Christoph Funke to the Lupin family as our Chief Technology Officer,” said Vinita Gupta, CEO of Lupin. “His proven track record in implementing innovative tech solutions and fostering a culture of digital excellence aligns perfectly with our vision for the future. Under his guidance, we are confident in accelerating our digital roadmap and unlocking new growth opportunities.”
As CTO, Funke will oversee Lupin’s global information technology strategy, cybersecurity, data analytics, and the integration of emerging technologies such as artificial intelligence, machine learning, and cloud computing across the organization’s operations.
“I am honored and excited to join Lupin, a company that has established itself as a leader in the pharmaceutical industry,” said Funke. “In today’s rapidly evolving digital landscape, technology plays a pivotal role in driving innovation, enhancing efficiencies, and delivering superior patient outcomes. I look forward to collaborating with the talented teams at Lupin to shape the future of healthcare through cutting-edge technological solutions.”
Funke’s appointment reinforces Lupin’s commitment to digital transformation and leveraging the power of technology to drive sustainable growth, improve patient experiences, and maintain its competitive edge in the global pharmaceutical market.
